Vyteris, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference

FAIR LAWN, NJ--(Marketwire - November 10, 2010) - Vyteris, Inc. (OTCBB: VYTR), developer of the first FDA-approved active transdermal patch and an innovator in alternative drug delivery technology, today announced that President and Chief Executive Officer Haro Hartounian, Ph.D., will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17 at 3:45 p.m. ET at the St. Regis Hotel in New York City. Dr. Hartounian will provide an overview of the Company and its proprietary smart patch technology as well as the Company’s merger agreement with MediSync Bioservices, a consolidator of contract research organizations and related businesses.

A live webcast of the presentation will be available on Vyteris’ website at http://investor.vyteris.com/events.cfm/. A replay will be archived on the “Events & Presentations” page in the Investors Information section of the Vyteris website.

About Vyteris, Inc.
Vyteris, Inc. is the maker of the first active, ready-to-use drug delivery patch (LidoSite®) to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris’ proprietary active transdermal smart patch technology delivers drugs comfortably through the skin using low-level electrical energy (iontophoresis). This smart patch technology is intended to allow precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economic, and lifestyle advantages over existing methods of drug administration. Vyteris has successfully delivered a peptide non-invasively using its system, where the Company demonstrated achievement of therapeutic levels of a peptide without using any needles. For more information, please visit us at www.vyteris.com.

Vyteris Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “would,” “should,” “believes,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption “Risk Factors” in its most recent Annual Report on Form 10-K and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.